{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:16:18Z","timestamp":1786979778094,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA039167"],"award-info":[{"award-number":["DA039167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA018151"],"award-info":[{"award-number":["DA018151"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["DA048586"],"award-info":[{"award-number":["DA048586"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00213-021-05965-x","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T23:37:51Z","timestamp":1629848271000},"page":"3463-3476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats"],"prefix":"10.1007","volume":"238","author":[{"given":"C. Austin","family":"Zamarripa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley M.","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Sufka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"5965_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tips.2016.11.002","volume":"38","author":"ML Banks","year":"2017","unstructured":"Banks ML, Negus SS (2017) Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci 38:181\u2013194. https:\/\/doi.org\/10.1016\/j.tips.2016.11.002","journal-title":"Trends Pharmacol Sci"},{"key":"5965_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00213-008-1458","volume":"12","author":"TC Beck","year":"2019","unstructured":"Beck TC, Hapstack MA, Beck KR, Dix TA (2019) Therapeutic potential of kappa opioid agonist. Pharmaceuticals 12:95. https:\/\/doi.org\/10.1007\/s00213-008-1458","journal-title":"Pharmaceuticals"},{"key":"5965_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41386-018-0125-6","volume":"44","author":"JB Becker","year":"2019","unstructured":"Becker JB, Chartoff E (2019) Sex differences in neural mechanisms mediating reward and addiction. Neuropsychopharmacology 44:166\u2013183. https:\/\/doi.org\/10.1038\/s41386-018-0125-6","journal-title":"Neuropsychopharmacology"},{"key":"5965_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fphar.2020.00188","volume":"11","author":"A Bedini","year":"2020","unstructured":"Bedini A, Di Cesare ML, Micheli L, Baiula M, Vaca G, De Marco R et al (2020) Functional selectivity and antinociceptive effects of a novel KOPr agonist. Front Pharmacol 11:188. https:\/\/doi.org\/10.3389\/fphar.2020.00188","journal-title":"Front Pharmacol"},{"key":"5965_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0014-2999(96)00698-x","volume":"317","author":"CA Bolanos","year":"1996","unstructured":"Bolanos CA, Garmsen GM, Clair MA, McDougall SA (1996) Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat. Eur J Pharmacol 317:1\u20138. https:\/\/doi.org\/10.1016\/s0014-2999(96)00698-x","journal-title":"Eur J Pharmacol"},{"key":"5965_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.brainresrev.2009.09.008","volume":"62","author":"AW Bruijnzeel","year":"2009","unstructured":"Bruijnzeel AW (2009) Kappa-opioid receptor signaling and brain reward function. Brain Res Rev 62:127\u2013146. https:\/\/doi.org\/10.1016\/j.brainresrev.2009.09.008","journal-title":"Brain Res Rev"},{"key":"5965_CR7","doi-asserted-by":"publisher","unstructured":"Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, et al (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9:ra117. https:\/\/doi.org\/10.1126\/scisignal.aai8441","DOI":"10.1126\/scisignal.aai8441"},{"key":"5965_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.pbb.2008.12.023","volume":"92","author":"SL Briggs","year":"2009","unstructured":"Briggs SL, Rech RH (2009) Antinociceptive interactions of micro- and kappa- opioid agonists in the colorectal distension assay in rats. Pharmacol Biochem Behav 92:343\u2013350. https:\/\/doi.org\/10.1016\/j.pbb.2008.12.023","journal-title":"Pharmacol Biochem Behav"},{"key":"5965_CR9","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1021\/acschemneuro.0c00407","volume":"11","author":"D Cao","year":"2020","unstructured":"Cao D, Huang P, Chiu YT, Chen C, Wang H, Li M et al (2020) Comparison of pharmacological properties between kappa opioid receptor agonist nalfurafine and 42B, its 3-dehydroxy analogue: disconnect between in vitro agonist bias and in vivo pharmacological effects. ACS Chem Neurosci 11:3026\u20133050. https:\/\/doi.org\/10.1021\/acschemneuro.0c00407","journal-title":"ACS Chem Neurosci"},{"key":"5965_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fnins.2015.00466","volume":"9","author":"EH Chartoff","year":"2015","unstructured":"Chartoff EH, Mavrikaki M (2015) Sex Differences in kappa opioid receptor function and their potential impact on addiction. Front Neurosci 9:466. https:\/\/doi.org\/10.3389\/fnins.2015.00466","journal-title":"Front Neurosci"},{"key":"5965_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.tips.2017.08.004","volume":"38","author":"HCS Chan","year":"2017","unstructured":"Chan HCS, McCarthy D, Li J, Palczewski K, Yuan S (2017) Designing safer analgesics via \u03bc-opioid receptor pathways. Trends Pharmacol Sci 38:1016\u20131037. https:\/\/doi.org\/10.1016\/j.tips.2017.08.004","journal-title":"Trends Pharmacol Sci"},{"key":"5965_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","volume":"62","author":"NA Crowley","year":"2015","unstructured":"Crowley NA, Kash TL (2015) Kappa opioid receptor signaling in the brain: circuitry and implications for treatment. Prog Neuropsychopharmacol Bio Psychiatry 62:51\u201360. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.01.001","journal-title":"Prog Neuropsychopharmacol Bio Psychiatry"},{"key":"5965_CR13","doi-asserted-by":"publisher","unstructured":"de Costa BR, Nuesch E, Kasteler R, Husni E, Welch V, Rutjex, AWS, et al (2014) Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev CD003115. https:\/\/doi.org\/10.1002\/14651858.CD003115.pub4","DOI":"10.1002\/14651858.CD003115.pub4"},{"key":"5965_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ijnp\/pyy034","volume":"21","author":"AD Dunn","year":"2018","unstructured":"Dunn AD, Reed B, Guariglia C, Dunn AM, Hillman JM, Kreek MJ (2018) Structurally Related kappa opioid receptor agonists with substantial differential signaling bias: neuroendocrine and behavioral effects in C57BL6 mice. Int J Neuropsychopharmacol 21:847\u2013857. https:\/\/doi.org\/10.1093\/ijnp\/pyy034","journal-title":"Int J Neuropsychopharmacol"},{"key":"5965_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0014-2999(99)00815-8","volume":"387","author":"T Endoh","year":"2000","unstructured":"Endoh T, Tajima A, Suzuki T, Kamei J, Narita M, Tseng L, Nagase H (2000) Characterization of the antinociceptive effects of TRK-820 in the rat. Eur J Pharmacol 387:133\u2013140. https:\/\/doi.org\/10.1016\/s0014-2999(99)00815-8","journal-title":"Eur J Pharmacol"},{"key":"5965_CR16","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1007\/s00213-015-3970-6","volume":"232","author":"SM Flax","year":"2015","unstructured":"Flax SM, Wakeford AG, Cheng K, Rice KC, Riley AL (2015) Effect of norbinaltorphimine on (9)-tetrahydrocannabinol (THC)-induced taste avoidance in adolescent and adult Sprague-Dawley rats. Psychopharmacology 232:3193\u20133201. https:\/\/doi.org\/10.1007\/s00213-015-3970-6","journal-title":"Psychopharmacology"},{"key":"5965_CR17","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","volume":"231","author":"KB Freeman","year":"2014","unstructured":"Freeman KB, Naylor JE, Prisinzano TE, Woolverton WL (2014) Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology 231:2751\u20132758. https:\/\/doi.org\/10.1007\/s00213-014-3436-2","journal-title":"Psychopharmacology"},{"key":"5965_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0006-8993(95)00306-b","volume":"681","author":"SD Glick","year":"1995","unstructured":"Glick SD, Maisonneuve IM, Raucci J, Archer S (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681:147\u2013152. https:\/\/doi.org\/10.1016\/0006-8993(95)00306-b","journal-title":"Brain Res"},{"key":"5965_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05519-7","author":"SL Huskinson","year":"2020","unstructured":"Huskinson SL, Platt DM, Brasfield M, Follett ME, Prisinzano TE, Blough BE et al (2020) Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-020-05519-7","journal-title":"Psychopharmacology"},{"key":"5965_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172702","volume":"864","author":"S Inan","year":"2019","unstructured":"Inan S, Huerta AT, Jensen LE, Dun NJ, Cowan A (2019) Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol 864:172702. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172702","journal-title":"Eur J Pharmacol"},{"key":"5965_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5055\/jom.2016.0321","volume":"12","author":"MR Jones","year":"2016","unstructured":"Jones MR, Kaye AD, Kaye AJ, Urman RD (2016) The emerging therapeutic roles of kappa-opioid agonists. J Opioid Manag 12:101\u2013107. https:\/\/doi.org\/10.5055\/jom.2016.0321","journal-title":"J Opioid Manag"},{"key":"5965_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178991","volume":"12","author":"K Kamimura","year":"2017","unstructured":"Kamimura K, Yokoo T, Kamimura H, Sakamaki A, Abe S, Tsuchiya A et al (2017) Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PLoS ONE 12:e0178991. https:\/\/doi.org\/10.1371\/journal.pone.0178991","journal-title":"PLoS ONE"},{"key":"5965_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/jpet.118.255661","volume":"371","author":"SW Kaski","year":"2019","unstructured":"Kaski SW, White AN, Gross JD, Trexler KR, Wix K, Harland AA et al (2019) Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine. J Pharmacol Exp Ther 371:487\u2013499. https:\/\/doi.org\/10.1124\/jpet.118.255661","journal-title":"J Pharmacol Exp Ther"},{"key":"5965_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.108.143925","volume":"328","author":"MC Ko","year":"2009","unstructured":"Ko MC, Husbands SM (2009) Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328:193\u2013200. https:\/\/doi.org\/10.1124\/jpet.108.143925","journal-title":"J Pharmacol Exp Ther"},{"key":"5965_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000341268","volume":"36","author":"H Kumagai","year":"2012","unstructured":"Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H et al (2012) Efficacy and safety of novel \u03ba-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 36:175\u2013183. https:\/\/doi.org\/10.1159\/000341268","journal-title":"Am J Nephrol"},{"key":"5965_CR26","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H (2010) Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on sever itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25:1251\u20131257. https:\/\/doi.org\/10.1093\/ndt\/gfp588","journal-title":"Nephrol Dial Transplant"},{"key":"5965_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.pain.2010.09.018","volume":"151","author":"KP Lawson","year":"2010","unstructured":"Lawson KP, Nag S, Thompson AD, Mokha SS (2010) Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia. Pain 151:806\u2013815. https:\/\/doi.org\/10.1016\/j.pain.2010.09.018","journal-title":"Pain"},{"key":"5965_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00213-017-4758-7","volume":"235","author":"ML Lazenka","year":"2018","unstructured":"Lazenka ML, Moerke MJ, Townsend EA, Freeman KB, Carroll FI, Negus SS (2018) Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain\/itch-stimulated and pain\/itch-depressed behaviors in male rats. Psychopharmacology 235:203\u2013213. https:\/\/doi.org\/10.1007\/s00213-017-4758-7","journal-title":"Psychopharmacology"},{"key":"5965_CR29","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00213-020-05530-y","volume":"237","author":"LP Legakis","year":"2020","unstructured":"Legakis LP, Karim-Nejad L, Negus SS (2020) Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats. Psychopharmacology 237:2201\u20132212. https:\/\/doi.org\/10.1007\/s00213-020-05530-y","journal-title":"Psychopharmacology"},{"key":"5965_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1476-5381.1988.tb10310.x","volume":"93","author":"GE Leighton","year":"1988","unstructured":"Leighton GE, Rodriguez RE, Hill RG, Hughes J (1988) Kappa-opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol 93:553\u2013560. https:\/\/doi.org\/10.1111\/j.1476-5381.1988.tb10310.x","journal-title":"Br J Pharmacol"},{"key":"5965_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1744-8069-10-62","volume":"10","author":"MD Leitl","year":"2014","unstructured":"Leitl MD, Potter DN, Cheng K, Rice KC, Carlezon WA, Negus SS (2014) Sustained pain-related depression of behavior: effects of intraplantar formalin and complete freund\u2019s adjuvant on intracranial self-stimulation (ICSS) and endogenous kappa opioid biomarkers in rats. Mol Pain 10:62. https:\/\/doi.org\/10.1186\/1744-8069-10-62","journal-title":"Mol Pain"},{"key":"5965_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/molecules23030681","volume":"23","author":"W Leppert","year":"2018","unstructured":"Leppert W, Malec-Milewska M, Zajaczkowska R, Wordliczek J (2018) Transdermal and Topical Drug Administration in the Treatment of Pain. Molecules 23:681. https:\/\/doi.org\/10.3390\/molecules23030681","journal-title":"Molecules"},{"key":"5965_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","volume":"44","author":"JJ Liu","year":"2019","unstructured":"Liu JJ, Chiu YT, Dimattio KM, Chen C, Huang P, Gentile TA et al (2019) Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in \u03ba opioid aversion. Neuropsychopharmacol 44:939\u2013949. https:\/\/doi.org\/10.1038\/s41386-018-0155-0","journal-title":"Neuropsychopharmacol"},{"key":"5965_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1124\/jpet.112.199851","volume":"344","author":"NJ Liu","year":"2013","unstructured":"Liu NJ, Schnell S, Wessendorf MW, Gintzler AR (2013) Sex, pain, and opioids: interdependent influences of sex and pain modality on dynorphin-mediated antinociception in rats. J Pharmacol Exp Ther 344:522\u2013530. https:\/\/doi.org\/10.1124\/jpet.112.199851","journal-title":"J Pharmacol Exp Ther"},{"key":"5965_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00213-012-2912-9","volume":"226","author":"KA MacLean","year":"2013","unstructured":"MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology 226:381\u2013392. https:\/\/doi.org\/10.1007\/s00213-012-2912-9","journal-title":"Psychopharmacology"},{"key":"5965_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pbb.2005.12.011","volume":"83","author":"CR McCurdy","year":"2006","unstructured":"McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ (2006) Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83:109\u2013113. https:\/\/doi.org\/10.1016\/j.pbb.2005.12.011","journal-title":"Pharmacol Biochem Behav"},{"key":"5965_CR37","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1124\/mol.111.074195","volume":"80","author":"EJ Melief","year":"2011","unstructured":"Melief EJ, Miyatake M, Carroll FI, Beguin C, Carlezon WA, Cohen BM et al (2011) Duration of action of a broad range of selective \u03ba-opioid receptor antagonists is positively correlated with C-Jun N-terminal kinase-1 activation. Mol Pharmacol 80:920\u2013929. https:\/\/doi.org\/10.1124\/mol.111.074195","journal-title":"Mol Pharmacol"},{"key":"5965_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0304-3959(92)90200-u","volume":"49","author":"C Miaskowski","year":"1992","unstructured":"Miaskowski C, Sutters KA, Taiwo YO, Levine JD (1992) Antinociceptive and motor effects of delta\/mu and kappa\/mu combinations of intrathecal opioid agonists. Pain 49:137\u2013144. https:\/\/doi.org\/10.1016\/0304-3959(92)90200-u","journal-title":"Pain"},{"key":"5965_CR39","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00213-018-4920-x","volume":"235","author":"V Minervini","year":"2018","unstructured":"Minervini V, Lu HY, Padarti J, Osteicoechea DC, France CP (2018) Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures. Psychopharmacology 235:2245\u20132256. https:\/\/doi.org\/10.1007\/s00213-018-4920-x","journal-title":"Psychopharmacology"},{"key":"5965_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fphar.2019.00407","volume":"10","author":"KL Mores","year":"2019","unstructured":"Mores KL, Cummins BR, Cassell RJ, van Rijn RM (2019) A review of the therapeutic potential of recently developed G protein-biased kappa agonists. Front Pharmacol 10:407. https:\/\/doi.org\/10.3389\/fphar.2019.00407","journal-title":"Front Pharmacol"},{"key":"5965_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00213-009-1770-6","volume":"210","author":"SS Negus","year":"2010","unstructured":"Negus SS, Morrissey EM, Rosenberg M, Cheng K, Rice KC (2010) Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats. Psychopharmacology 210:149\u2013159. https:\/\/doi.org\/10.1007\/s00213-009-1770-6","journal-title":"Psychopharmacology"},{"key":"5965_CR42","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1097\/j.pain.0000000000000171","volume":"156","author":"SS Negus","year":"2015","unstructured":"Negus SS, Neddenriep B, Altarifi AA, Carroll FI, Leitl MD, Miller LL (2015) Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice. Pain 156:1153\u20131160. https:\/\/doi.org\/10.1097\/j.pain.0000000000000171","journal-title":"Pain"},{"key":"5965_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1124\/jpet.111.186783","volume":"340","author":"SS Negus","year":"2012","unstructured":"Negus SS, O\u2019Connell R, Morrissey E, Cheng K, Rice KC (2012) Effects of peripherally restricted \u03ba opioid receptor agonists on pain-related stimulation and depression of behavior in rats. J Pharmacol Exp Ther 340:501\u2013509. https:\/\/doi.org\/10.1124\/jpet.111.186783","journal-title":"J Pharmacol Exp Ther"},{"key":"5965_CR44","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/a0013088","volume":"16","author":"SS Negus","year":"2008","unstructured":"Negus SS, Schrode K, Stevenson GW (2008) Micro\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386\u2013399. https:\/\/doi.org\/10.1037\/a0013088","journal-title":"Exp Clin Psychopharmacol"},{"key":"5965_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1054\/jpai.2002.124734","volume":"3","author":"SS Negus","year":"2002","unstructured":"Negus SS, Zuzga DS, Mello NK (2002) Sex differences in opioid antinociception in rhesus monkeys: antagonism of fentanyl and U50,488 by quadazocine. J Pain 3:218\u2013226. https:\/\/doi.org\/10.1054\/jpai.2002.124734","journal-title":"J Pain"},{"key":"5965_CR46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","volume":"72","author":"M Ranganathan","year":"2012","unstructured":"Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA et al (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biol Psychiatry 72:871\u2013879. https:\/\/doi.org\/10.1016\/j.biopsych.2012.06.012","journal-title":"Biol Psychiatry"},{"key":"5965_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","volume":"26","author":"Z Rankovic","year":"2016","unstructured":"Rankovic Z, Brust TF, Bohn LM (2016) Biased agonism: an emerging paradigm in GPCR drug discovery. Bioorg Med Chem Lett 26:241\u2013250. https:\/\/doi.org\/10.1016\/j.bmcl.2015.12.024","journal-title":"Bioorg Med Chem Lett"},{"key":"5965_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","volume":"32","author":"SS Schattauer","year":"2017","unstructured":"Schattauer SS, Kuhar JR, Song A, Chavkin C (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell Signal 32:59\u201365. https:\/\/doi.org\/10.1016\/j.cellsig.2017.01.016","journal-title":"Cell Signal"},{"key":"5965_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1749-6632.2001.tb03558.x","volume":"937","author":"TS Shippenberg","year":"2001","unstructured":"Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA (2001) Modulation of the behavioral and neuroshemical effects of psychostimulants by kappa-opioid receptor systems. Ann N Y Acad Sci 937:50\u201373. https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb03558.x","journal-title":"Ann N Y Acad Sci"},{"key":"5965_CR50","doi-asserted-by":"publisher","DOI":"10.1201\/9781420036107","volume-title":"Drug synergism and dose-effect data analysis","author":"RJ Tallarida","year":"2000","unstructured":"Tallarida RJ (2000) Drug synergism and dose-effect data analysis. Champman and Hall\/CRC, Boca Raton"},{"key":"5965_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.112.193474","volume":"342","author":"RJ Tallarida","year":"2012","unstructured":"Tallarida RJ (2012) Revisiting the isoboloe and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther 342:2\u20138. https:\/\/doi.org\/10.1124\/jpet.112.193474","journal-title":"J Pharmacol Exp Ther"},{"key":"5965_CR52","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.1523\/JNEUROSCI.2077-05.2005","volume":"25","author":"M Thomsen","year":"2005","unstructured":"Thomsen M, Woldbye DP, Wortwein G, Fink-Jensen A, Wess J, Caine SB (2005) Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mic. J Neurosci 25:8141\u20138149. https:\/\/doi.org\/10.1523\/JNEUROSCI.2077-05.2005","journal-title":"J Neurosci"},{"key":"5965_CR53","doi-asserted-by":"publisher","unstructured":"Townsend EA (2021) Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration. Psychopharmacology (Berl) https:\/\/doi.org\/10.1007\/s00213-020-05749-9","DOI":"10.1007\/s00213-020-05749-9"},{"key":"5965_CR54","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","volume":"234","author":"EA Townsend","year":"2017","unstructured":"Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW (2017) Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology 234:2597\u20132605. https:\/\/doi.org\/10.1007\/s00213-017-4652-3","journal-title":"Psychopharmacology"},{"key":"5965_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.106.104463","volume":"320","author":"JD Urban","year":"2007","unstructured":"Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1\u201313. https:\/\/doi.org\/10.1124\/jpet.106.104463","journal-title":"J Pharmacol Exp Ther"},{"key":"5965_CR56","first-page":"151","volume":"24","author":"ZX Xi","year":"1998","unstructured":"Xi ZX, Fuller SA, Stein EA (1998) Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study. J Pharmacol Exp Ther 24:151\u2013161","journal-title":"J Pharmacol Exp Ther"},{"key":"5965_CR57","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","volume":"237","author":"CA Zamarripa","year":"2020","unstructured":"Zamarripa CA, Naylor JE, Huskinson SL, Townsend EA, Prisinzano TE, Freeman KB (2020a) Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. Psychopharmacology 237:1471\u20131480. https:\/\/doi.org\/10.1007\/s00213-020-05473-4","journal-title":"Psychopharmacology"},{"key":"5965_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000581","author":"CA Zamarripa","year":"2020","unstructured":"Zamarripa CA, Patel TR, Williams BC, Pareek T, Schrock HM, Prisinzano TE, Freeman KB (2020b) The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone\u2019s conditioned rewarding effects in male rats. Behav Pharmacol. https:\/\/doi.org\/10.1097\/FBP.0000000000000581","journal-title":"Behav Pharmacol"},{"key":"5965_CR59","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","volume":"192","author":"CA Zamarripa","year":"2018","unstructured":"Zamarripa CA, Edwards SR, Qureshi HN, Yi JN, Blough BE, Freeman KB (2018) The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats. Drug Alcohol Depend 192:158\u2013162. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.002","journal-title":"Drug Alcohol Depend"},{"key":"5965_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108244","volume":"176","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Kreek MJ (2020) Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL\/6J mice. Neuropharmacology 176:108244. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108244","journal-title":"Neuropharmacology"},{"key":"5965_CR61","doi-asserted-by":"publisher","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","volume":"288","author":"L Zhou","year":"2013","unstructured":"Zhou L, Lovell KM, Franskowski KJ, Slauson SR, Philips AM, Streicher JM et al (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Bio Chem 288:36703-36716. https:\/\/doi.org\/10.1074\/jbc.M113.504381","journal-title":"J Bio Chem"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05965-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05965-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T08:08:24Z","timestamp":1638173304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05965-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5965"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05965-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}